Behçet and LDH/Albumin

ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls.

Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Behcet's Disease Albumin Behcet Syndrome Cardiovascular Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Disease Severity Eye Diseases Genetic Diseases, Inborn Hereditary Autoinflammatory Diseases Lactate Dehydrogenase Mouth Diseases Panuveitis Skin Diseases Skin Diseases, Genetic Skin Diseases, Vascular Skin and Connective Tissue Diseases Stomatognathic Diseases Uveal Diseases Uveitis Uveitis, Anterior Vascular Diseases Vasculitis

Age range

18 year–69 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Erdal Pala

Erzurum, 25240, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with Behçet's disease aged 18-69

Exclusion criteria

younger than 18 years or older than 69 years, pregnant and lactating patients, patients with acute infection on admission or nutritional problems, symptomatic gastrointestinal symptoms, malignancy, hepatitis or liver disease were excluded.

Treatment and study plan

LDH/albumin ratio

Diagnostic Test

LDH/Albumin ratios of patient and control groups were recorded.

Primary outcomes

LDH/albumin ratio

Time frame: February 2020 and April 2023

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

A Convenient Parameter for Predicting Behçet's Disease Severity: Lactate Dehydrogenase/Albumin Ratio

Important dates

Study start: 2020
Primary completion: 2023
Study completion: 2023
First posted: Feb 26, 2024
Registry last updated: Feb 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed